Actemra
DOSING GUIDE

A guide to assist healthcare professionals with the dose preparation and administration of Actemra therapy in patients with:

- Rheumatoid Arthritis [Intravenous]
-
- Polyarticular Juvenile Idiopathic Arthritis (also referred to as Juvenile Idiopathic Polyarthritis) [Intravenous]
- Systemic Juvenile Idiopathic Arthritis [Intravenous]

Health Authority Approval Date: February - 2020

Contents

This Actemra Dosing Guide [is a requirement of the Actemra product license and] contains important safety information that you need to be aware of when administering Actemra. This Actemra Dosing Guide must be read together with the Actemra Healthcare Professional and Patient Brochures [available online at www.phar,am website address and the Actemra Labeling/Summary of Product Characteristics that comes with Actemra as it contains important information about Actemra.

Please read this information carefully before administering the product.

Actemra IV (Actemra 20 mg/ml concentrate for solution for infusion):

Actemra, in combination with methotrexate (MTX), is indicated for:

the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients. Tocilizumab can be used alone or in combination with methotrexate (MTX) and/or other diseasemodifying anti-rheumatic drugs (DMARDs). Tocilizumab has been shown to inhibit progression of joint damage as measured by X-ray and to improve physical functionActemra (Tocilizumab) is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older. Tocilizumab can be given alone or in combination with MTX. Actemra (Tocilizumab) is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. Tocilizumab can be given alone or in combination with MTX.

Prior to starting treatment with Actemra:

- It is important that you review the pre-administration checklist found in the Patient Brochure: ***Before starting treatment with Actemra® (tocilizumab)*** with your patient, the patient's parents/guardians, or both.
- Allow ample time to discuss any questions your patient, the patient's parents/guardians, or both may have.
- It is important that you review the information contained within the *Healthcare Professional Brochure* for Actemra® (tocilizumab) intravenous (IV) and the Patient Brochure: ***Before starting treatment with Actemra® (tocilizumab)*** with your patient, the patient's parents/guardians, or both. These will help them understand what they may expect from the treatment of the patient's condition with Actemra.

For full information, see the Summary of Product Characteristics (SmPC) and the Actemra Package Leaflet: Information for the user, which can be found on the website of SCIENTIFIC CENTRE OF DRUG AND MEDICAL TECHNOLOGY EXPERTISE AFTER ACADEMICIAN E. GABRIELYAN CJSC (www.pharm.am)

Actemra Patient Brochures and other information can be requested from your local responsibles . If you have questions or concerns, please visit www.pharm.am or call +37491796688

PART I – INTRAVENOUS (IV) ADMINISTRATION OF ACTEMRA BY INFUSION

This guide will walk you through the Actemra infusion process in 6 steps

1 WEIGH PATIENT AND CALCULATE ACTEMRA DOSE BASED ON INDICATION

Actemra dosing is calculated based on each patient's weight and the indication for which they are treated. The treatment frequency varies by indication. Verify the patient's weight and indication, then locate it on the chart to find the corresponding dose and recommended vial combination.

If the patient's dose has been calculated prior to the infusion date, take his or her weight to make sure that it has not changed from the time of the original calculation to require a change in dose. If the patient's weight has changed, contact the prescriber to discuss whether a dosing change is needed. Refer to the chart to check whether a dosing adjustment is necessary.

Once the dose is calculated, choose the vial combination of Actemra that best matches the patient's needs. Actemra is available in three different dosing vials:

 400 mg (20 ml) vials 200 mg (10 ml) vials  80 mg (4 ml) vials

Inspect the vials for particulate matter and discolouration. Only solutions which are clear to opalescent, colourless to pale yellow and free of visible particles should be used.

RA: Dosing Preparation and Administration Guide with Actemra IV

Actemra IV dosing in RA patients is calculated based on each patient's weight as follows:

For the 8 mg/kg dose: Patient weight (kg) x 8 (mg/kg) = Actemra 8 mg

For individuals whose body weight is more than 100 kg, doses exceeding 800 mg per infusion are not recommended.

8 mg/kg dose

Weight (kg)	Weight (lbs)	Dose (mg)	Dose (mL)	Vial combinations
50	110.0	400	20.0	
52	114.4	416	20.8	
54	118.8	432	21.6	
56	123.2	448	22.4	
58	127.6	464	23.2	
60	132.0	480	24.0	
62	136.4	496	24.8	
64	140.8	512	25.6	
66	145.2	528	26.4	
68	149.6	544	27.2	
70	154.0	560	28.0	
72	158.4	576	28.8	
74	162.8	592	29.6	
76	167.2	608	30.4	
78	171.6	624	31.2	
80	176.0	640	32.0	
82	180.4	656	32.8	
84	184.8	672	33.6	
86	189.2	688	34.4	
88	193.6	704	35.2	
90	198.0	720	36.0	
92	202.4	736	36.8	
94	206.8	752	37.6	
96	211.2	768	38.4	
98	215.6	784	39.2	
≥100	≥220.0	800	40.0	

pJIA: Dosing Preparation and Administration Guide with Actemra IV

Dosing should take place at 4-week intervals.

A change in dose of 8mg/kg or 10 mg/kg should only be based on a consistent change in the patient's body weight over time (e.g., within 3 weeks). If the patient's weight has changed, contact the prescriber to discuss whether a dosing change is needed. Refer to the chart to check whether a dosing adjustment is necessary.

Actemra IV dosing in pJIA patients is calculated based on each patient's weight as follows:

For patients weighing <30 kg: Patient's weight (kg) x 10 mg/kg = Actemra dose

For patients weighing ≥30 kg: Patient's weight (kg) x 8 mg/kg = Actemra dose



Weight (kg)	Weight (lbs)	Dose (mg)	Dose (ml)	Vial combinations
10	22.0	100	5.0	
12	26.4	120	6.0	
14	30.8	140	7.0	
16	35.2	160	8.0	
18	39.6	180	9.0	
20	44.0	200	10.0	
22	48.4	220	11.0	
24	52.8	240	12.0	
26	57.2	260	13.0	
28	61.6	280	14.0	
30	66.0	240	12.0	
32	70.4	256	12.8	
34	74.8	272	13.6	
36	79.2	288	14.4	
38	83.6	304	15.2	
40	88.0	320	16.0	
42	92.4	336	16.8	
44	96.8	352	17.6	
46	101.2	368	18.4	
48	105.6	384	19.2	
50	110.0	400	20.0	
52	114.4	416	20.8	
54	118.8	432	21.6	
56	123.2	448	22.4	
58	127.6	464	23.2	
60	132.0	480	24.0	
62	136.4	496	24.8	
64	140.8	512	25.6	
66	145.2	528	26.4	
68	149.6	544	27.2	
70	154.0	560	28.0	
72	158.4	576	28.8	
74	162.8	592	29.6	
76	167.2	608	30.4	
78	171.6	624	31.2	
80	176.0	640	32.0	
82	180.4	656	32.8	
84	184.8	672	33.6	
86	189.2	688	34.4	
88	193.6	704	35.2	
90	198.0	720	36.0	
92	202.4	736	36.8	
94	206.8	752	37.6	
96	211.2	768	38.4	
98	215.6	784	39.2	
≥100	≥220.0	800	40.0	

sJIA: Dosing Preparation and Administration Guide with Actemra IV

Dosing should take place at 2-week intervals.

A change in dose of 8mg/kg or 12 mg/kg should only be based on a consistent change in the patient's body weight over time (e.g., within 3 weeks). If the patient's weight has changed, contact the prescriber to discuss whether a dosing change is needed. Refer to the chart to check whether a dosing adjustment is necessary.

Actemra dosing in sJIA patients is calculated based on each patient's weight as follows:

For patients weighing <30 kg: Patient's weight (kg) x 12 mg/kg = Actemra dose

For patients weighing ≥30 kg: Patient's weight (kg) x 8 mg/kg = Actemra dose



Weight (kg)	Weight (lbs)	Dose (mg)	Dose (ml)	Vial combinations
10	22.0	120	6.0	
12	26.4	144	7.2	
14	30.8	168	8.4	
16	35.2	192	9.6	
18	39.6	216	10.8	
20	44.0	240	12.0	
22	48.4	264	13.2	
24	52.8	288	14.4	
26	57.2	312	15.6	
28	61.6	336	16.8	
30	66.0	240	12.0	
32	70.4	256	12.8	
34	74.8	272	13.6	
36	79.2	288	14.4	
38	83.6	304	15.2	
40	88.0	320	16.0	
42	92.4	336	16.8	
44	96.8	352	17.6	
46	101.2	368	18.4	
48	105.6	384	19.2	
50	110.0	400	20.0	
52	114.4	416	20.8	
54	118.8	432	21.6	
56	123.2	448	22.4	
58	127.6	464	23.2	
60	132.0	480	24.0	
62	136.4	496	24.8	
64	140.8	512	25.6	
66	145.2	528	26.4	
68	149.6	544	27.2	
70	154.0	560	28.0	
72	158.4	576	28.8	
74	162.8	592	29.6	
76	167.2	608	30.4	
78	171.6	624	31.2	
80	176.0	640	32.0	
82	180.4	656	32.8	
84	184.8	672	33.6	
86	189.2	688	34.4	
88	193.6	704	35.2	
90	198.0	720	36.0	
92	202.4	736	36.8	
94	206.8	752	37.6	
96	211.2	768	38.4	
98	215.6	784	39.2	
≥100	≥220.0	800	40.0	

CRS: Dosing Preparation and Administration Guide with Actemra IV

If no clinical improvement in the signs and symptoms of CRS occurs after the first dose, up to 3 additional doses of ACTEMRA may be administered. The interval between consecutive doses should be at least 8 hours.

Doses exceeding 800 mg per infusion are not recommended in CRS patients.

administration is not approved for CRS.

Actemra dosing in CRS patients is calculated based on each patient's weight as follows:

For patients weighing <30 kg: Patient's weight (kg) x 12 mg/kg = Actemra dose

For patients weighing ≥30 kg: Patient's weight (kg) x 8 mg/kg = Actemra dose

2 GATHER ALL NECESSARY SUPPLIES

You will need:

- Actemra, at room temperature
- Syringes and large-bore needles
- One primary infusion set
- One 100 ml or 50 ml (for patients <30kg) bag of 0.9% (9 mg/mL) sterile,non-pyrogenic sodium chloride solution for injection
- One intravenous (IV) catheter
- Gauze
- Tourniquet
- Gloves
- Alcohol/cleansing wipes

3 TAKE BASELINE ASSESSMENTS

Take baseline assessments to ensure the patient is healthy enough to receive the infusion.

Vital signs may include:

- Blood pressure
- Temperature
- Pulse

Follow the recommended baseline patient questions as described in the Actemra Healthcare Professional Brochure (Section 15 – General Recommendation) as well as the Summary of Product Characteristics (Section 4.4 – Warnings and Precautions).

4 PREPARE THE PATIENT FOR THE INFUSION

Review the Patient Brochure: ***Before starting treatment with Actemra® (tocilizumab)*** with the patient. Answer any questions he or she might have

Actemra does not require premedication

5 PREPARE THE ACTEMRA INFUSION

Actemra is a ready-mix solution and requires no reconstitution. The expiry date should always be checked before use. The Actemra concentrate for IV infusion should be diluted by a healthcare professional using aseptic technique.

- Actemra should be refrigerated for storage. However, the fully diluted Actemra solution should be allowed to reach room temperature before it is infused.
- The fully diluted Actemra solutions for infusion may be stored at 2°C–8°C or room temperature (if diluted under controlled and validated aseptic conditions) for up to 24 hours and should be protected from light.
- Actemra solutions do not contain preservatives; therefore, unused product remaining in the vials should not be used.
- **Weight-/indication-based dosing:**

- **For RA, CRS, sJIA (>30 kg), and pJIA (>30 kg):** From a 100 ml infusion bag withdraw a volume of 0.9% (9 mg/ml) sterile, non-pyrogenic sodium chloride solution for injection equal to the volume of the Actemra solution required for the patient's dose.
- **For sJIA and pJIA patients < 30 kg:** Use a 50ml infusion bag withdraw a volume of 0.9% (9 mg/ml) sterile, non-pyrogenic sodium chloride solution for injection equal to the volume of the Actemra solution required for the patient's dose.

- Actemra should not be infused concomitantly in the same IV line with other medications. No physical or biochemical compatibility studies have been conducted to evaluate the co-administration of Actemra with other medications.
- Slowly add Actemra concentrate for IV infusion from each vial into the infusion bag. To mix the solution, gently invert the bag to avoid foaming.
- Parenteral medicinal products should be inspected visually for particulate matter and discolouration prior to administration. Only solutions which are clear to opalescent, colourless to pale yellow and free of visible particles should be diluted.
- Dispose of needle and syringe in sharps containers when finished.

6 BEGIN THE ACTEMRA INFUSION

The infusion should be administered over 60 minutes. It must be administered with an infusion set and should never be administered as an IV push or bolus.

- Prior to the infusion, inform the patient that serious allergic reactions including anaphylaxis have been reported in association with Actemra. Such reactions may be more severe, and potentially fatal, in patients who have experienced allergic reactions during previous treatment with Actemra even if they have received premedication with steroids and antihistamines. Most allergic reactions occur during infusion or within 24 hours of Actemra administration, although allergic reactions can occur at any time.
- If an anaphylactic reaction or other serious hypersensitivity reaction occurs, administration of Actemra should be stopped immediately, appropriate therapy initiated and Actemra should be permanently discontinued. Fatal anaphylaxis has been reported after marketing authorisation during treatment with IV Actemra.
- Instruct the patient to **seek immediate medical attention** if they notice any of the following signs or symptoms of systemic allergic reactions after receiving Actemra:
    - Rash, itching or hives
    - Shortness of breath or trouble breathing
    - Swelling of the lips, tongue or face
    - Chest pain
    - Feeling dizzy or faint
    - Severe stomach pain or vomiting
    - Hypotension

Once the infusion is completed, remove the catheter and dispose of all supplies properly, clean and bandage the infusion site and check the patient's vital signs.

Product traceability

In order to improve the traceability of biological medicinal products, the tradename and batch number of the administered product should be clearly recorded (or stated) in the patient file.

Call for reporting

If the patient experiences any side effects, talk to the doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.

You can also report side effects directly via [the national reporting system]. By reporting side effects, you or the patient can help provide more information on the safety of this medicine.

Please report side-effects to: Medical Manager, Local Safety Responsible of Hoffmann-La Roche products in Armenia /LSR Gayane Ghazaryan: mob.: +374 91 796688/ email: gayaneh.ghazaryan@gmail.com, or Nune Karapetyan, mob: +374 91 721153/ email: nune.karapetyan.roche@gmail.com. Also direct your reports to Roche Moscow DS Hub via following contacts: tel.: +7-495-229 2999, Fax: +7-495- 229 7999/ email: moscow.ds@roche.com; website: www.roche.ru.

Or report via national reporting procedure by addressing your report to "Scientific Centre of Drug and Medical Technology Expertise after academician E.Gabrielyan" CJSC by following contacts: Address: 49/4 Komitas av., 0051 Yerevan, Armenia. HOT LINE: (+ 374 10) 20-05-05, (+374 10) 22-05-05 ; email: vigilance@pharm.am or website: www.pharm.am

For full information on all possible side effects please see the Actemra Package Leaflet, which can be found at the Scientific Centre of Drug and Medical Technology Expertise after academician E.Gabrielyan" CJSC website (www.pharm.am)

Gayane Ghazaryan _____ 10.02.2020

Medical Manager of Hoffmann-La Roche products in Armenia

Nune Karapetyan _____ 10.02.2020

Commercial Lead of Hoffmann-La Roche products in Armenia

Health Authority Approval Date: February - 2020